Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphocyte response to mitogens in progressive systemic sclerosis.

N B Salem, J H Morse

    Arthritis and Rheumatism
    |September 1, 1976
    PubMed
    Summary

    Progressive systemic sclerosis (PSS) patients with multisystem involvement showed reduced lymphocyte responses to Con A and PWM. However, PSS patients with myositis maintained normal lymphocyte function, suggesting distinct immune profiles in PSS subtypes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.

    The European respiratory journal·2004
    Same author

    Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.

    The European respiratory journal·2004
    Same author

    Genetic studies of pulmonary arterial hypertension.

    Lupus·2003
    Same author

    BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives.

    The European respiratory journal·2002
    Same author

    Genetic aspects of pulmonary arterial hypertension.

    Annals of medicine·2002
    Same author

    Elevated plasma tissue plasminogen activator and anti-THP-1 antibodies are independently associated with decreased graft survival in cardiac transplant recipients.

    The American journal of cardiology·2001

    Area of Science:

    • Immunology
    • Rheumatology
    • Clinical Medicine

    Background:

    • Progressive systemic sclerosis (PSS) is an autoimmune disease characterized by widespread connective tissue abnormalities.
    • Immune system dysregulation, particularly T-cell function, is implicated in PSS pathogenesis.
    • Understanding lymphocyte responses to mitogens can provide insights into immune cell activity in PSS.

    Purpose of the Study:

    • To investigate lymphocyte proliferation responses to common mitogens in patients with progressive systemic sclerosis.
    • To determine if specific clinical subsets of PSS exhibit distinct patterns of lymphocyte reactivity.
    • To correlate lymphocyte function with serological markers in PSS patients.

    Main Methods:

    • Lymphocyte responses were assessed using phytohemagglutinin P (PHA-P), concanavallin A (Con A), and pokeweed (PWM) stimulation assays.

    Related Experiment Videos

  • Eighteen patients diagnosed with PSS were included in the study.
  • Patient responses were compared to those of healthy controls, and subgroups based on clinical involvement (multisystem, myositis) were analyzed.

    • Main Results:

    • A significant decrease in lymphocyte response to Con A and PWM was observed in PSS patients with multisystem involvement compared to controls.
    • PSS patients with myositis, despite multisystem involvement, demonstrated normal lymphocyte responses to all tested mitogens (PHA-P, Con A, PWM).
    • Phytohemagglutinin P (PHA-P) stimulation yielded normal responses across all PSS patient groups.

    Conclusions:

    • Lymphocyte hyporesponsiveness to specific mitogens (Con A, PWM) may be a feature of PSS with extensive multisystem disease.
    • The presence of myositis in PSS patients appears to be associated with preserved lymphocyte function.
    • Abnormal lymphocyte function in PSS correlates with the presence of antinuclear antibodies, elevated sedimentation rates, and positive latex fixation, suggesting a link between immune cell activity and specific disease markers.